Pfizer Just Announced a New Lyme Disease Vaccine
Women's Health • • business
Key Points:
- Pfizer and Valneva announced phase 3 trial results for PF-0730740, a four-dose Lyme disease vaccine about 70% effective at preventing infection in individuals aged 5 and older across the U.S., Canada, and Europe.
- Lyme disease affects nearly half a million Americans annually and is caused by bacteria transmitted by deer ticks; symptoms range from fever and fatigue to severe neurological and cardiac complications if untreated.
- The previous Lyme vaccine, Lymerix, was withdrawn from the market due to poor public uptake and unfounded safety concerns despite nearly 80% efficacy, highlighting challenges in vaccine acceptance.
- Experts note the new vaccine’s 70% effectiveness is meaningful, especially for people in high-risk areas engaging in outdoor activities, though it remains unclear if it reduces disease complications.
- Vaccination is recommended primarily for those living in Lyme-endemic regions, while preventive measures like insect repellent and tick checks remain important for all.
